Benefit of Blinatumomab in Kids With Relapsed B-Cell Lymphoma

NEW YORK (Reuters Health) – Two randomized trials show a clear benefit of blinatumomab in combination with conventional chemotherapy in children with high-risk relapsed B-cell acute lymphoblastic leukemia (B-ALL), with improved outcomes and a favorable toxicity profile. In one study, 108 children (mean age, 5 years) with high-risk relapsed B-ALL received one cycle of reinduction chemotherapy and two cycles of […]
Continue reading »